HIV-ASSOCIATED VENOUS THROMBOEMBOLISM
HIV infection has been recognized as a prothrombotic condition and this association has now been proven by a large number of studies with a reported VTE frequency among HIV-infected patients ranging from 0.19% to 7,63 %/year. HIV infection is associated with a two to tenfold increased risk of venous...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PAGEPress Publications
2011-07-01
|
| Series: | Mediterranean Journal of Hematology and Infectious Diseases |
| Subjects: | |
| Online Access: | http://www.mjhid.org/index.php/mjhid/article/view/284 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846096516862705664 |
|---|---|
| author | Michele Bibas Gianluigi Biava Andrea Antinori |
| author_facet | Michele Bibas Gianluigi Biava Andrea Antinori |
| author_sort | Michele Bibas |
| collection | DOAJ |
| description | HIV infection has been recognized as a prothrombotic condition and this association has now been proven by a large number of studies with a reported VTE frequency among HIV-infected patients ranging from 0.19% to 7,63 %/year. HIV infection is associated with a two to tenfold increased risk of venous thrombosis in comparison with a general population of the same age. Some risk factors demonstrated a strongest association with VTE such as, low CD4+ cell count especially in the presence of clinical AIDS, protein S deficiency, and protein C deficiency. Whereas other risk factors are still controversial like protease inhibitor therapy, presence of active opportunistic infections and presence of antiphospholipid antibodies, including anticardiolipin antibodies and lupus anticoagulant. Physicians caring for HIV positive patients should be able to recognize and treat not only the well-known opportunistic infections and malignancies associated with this chronic disease, but also be alert to the less well-known complications such as thromboses. Pulmonary embolism should be included in the differential diagnosis when patients with HIV/AIDS have unexplained dyspnea or hypoxemia. In younger individuals with VTE, especially men, without other identifiable risk factors for VTE, HIV should be considered. Because interactions between warfarin and antiretrovirals is possible, health care providers should also be alert to the potential of dangerously high or low INRs when they are giving anticoagulants to patients with HIV infection who are undergoing antiretroviral therapy. |
| format | Article |
| id | doaj-art-db177467aa264c939bd2e3f4fd407184 |
| institution | Kabale University |
| issn | 2035-3006 |
| language | English |
| publishDate | 2011-07-01 |
| publisher | PAGEPress Publications |
| record_format | Article |
| series | Mediterranean Journal of Hematology and Infectious Diseases |
| spelling | doaj-art-db177467aa264c939bd2e3f4fd4071842025-01-02T06:45:38ZengPAGEPress PublicationsMediterranean Journal of Hematology and Infectious Diseases2035-30062011-07-0131e2011030e201103010.4084/mjhid.2011.030176HIV-ASSOCIATED VENOUS THROMBOEMBOLISMMichele Bibas0Gianluigi BiavaAndrea AntinoriNational Institute for Infectious Diseases “Lazzaro Spallanzani”,HIV infection has been recognized as a prothrombotic condition and this association has now been proven by a large number of studies with a reported VTE frequency among HIV-infected patients ranging from 0.19% to 7,63 %/year. HIV infection is associated with a two to tenfold increased risk of venous thrombosis in comparison with a general population of the same age. Some risk factors demonstrated a strongest association with VTE such as, low CD4+ cell count especially in the presence of clinical AIDS, protein S deficiency, and protein C deficiency. Whereas other risk factors are still controversial like protease inhibitor therapy, presence of active opportunistic infections and presence of antiphospholipid antibodies, including anticardiolipin antibodies and lupus anticoagulant. Physicians caring for HIV positive patients should be able to recognize and treat not only the well-known opportunistic infections and malignancies associated with this chronic disease, but also be alert to the less well-known complications such as thromboses. Pulmonary embolism should be included in the differential diagnosis when patients with HIV/AIDS have unexplained dyspnea or hypoxemia. In younger individuals with VTE, especially men, without other identifiable risk factors for VTE, HIV should be considered. Because interactions between warfarin and antiretrovirals is possible, health care providers should also be alert to the potential of dangerously high or low INRs when they are giving anticoagulants to patients with HIV infection who are undergoing antiretroviral therapy.http://www.mjhid.org/index.php/mjhid/article/view/284HIV , VTE , Thrombosis ,Infectious disease |
| spellingShingle | Michele Bibas Gianluigi Biava Andrea Antinori HIV-ASSOCIATED VENOUS THROMBOEMBOLISM Mediterranean Journal of Hematology and Infectious Diseases HIV , VTE , Thrombosis ,Infectious disease |
| title | HIV-ASSOCIATED VENOUS THROMBOEMBOLISM |
| title_full | HIV-ASSOCIATED VENOUS THROMBOEMBOLISM |
| title_fullStr | HIV-ASSOCIATED VENOUS THROMBOEMBOLISM |
| title_full_unstemmed | HIV-ASSOCIATED VENOUS THROMBOEMBOLISM |
| title_short | HIV-ASSOCIATED VENOUS THROMBOEMBOLISM |
| title_sort | hiv associated venous thromboembolism |
| topic | HIV , VTE , Thrombosis ,Infectious disease |
| url | http://www.mjhid.org/index.php/mjhid/article/view/284 |
| work_keys_str_mv | AT michelebibas hivassociatedvenousthromboembolism AT gianluigibiava hivassociatedvenousthromboembolism AT andreaantinori hivassociatedvenousthromboembolism |